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A B S T R A C T
Objective: Peripheral sensory neuropathy (PSN) is a common cause of ulceration and amputation in di-
abetes (DM) patients. The prevalence of PSN in DM patients is largely undetermined in sub-Saharan African
population. We studied the burden of PSN in DM patients using a validated questionnaire and quanti-
tative sensory test.
Methods: In a case-control design, PSN was measured in 491 DM patients and 330 non-DM controls using
Michigan neuropathy screening instrument (MNSI) and vibration perception threshold (VPT). PSN was
deﬁned as MNSI symptom score ≥7, MNSI examination score ≥2 or VPT ≥25V.
Results: The prevalence of PSN screened by MNSI symptom score, MNSI examination score and VPT was
7.1%, 51.5% and 24.5% in DM patients; and 1.5%, 24.5% and 8.5% in non-DM participants respectively. The
major determinants of PSN screened by MNSI examination score were diabetes status [OR (95% CI): 4.31
(2.94–6.31), p < 0.001], age [1.03 (1.01–1.05), p < 0.001], previous [4.55 (2.11–9.82), p < 0.001] and current
[8.16 (3.77–17.68), p < 0.001] smoking status. The major determinants of PSN screened by VPT were di-
abetes status [1.04 (1.02–1.06), p < 0.001], age [1.02 (1.01–1.03), p = 0.047], heart rate [1.78 (1.08–2.92),
p = 0.023], second-hand smoking [3.66 (2.26–5.95), p < 0.001] and body height [3.28 (1.65–8.42), p = 0.015].
Conclusion: Our study has shown high burden of PSN in DM patients in Ghana using simple, accurate,
and non-invasive screening tools like MNSI and neurothesiometer.
© 2016 Published by Elsevier Inc.
Introduction
Epidemiological transition has been under way in sub-Saharan
Africa and this is in association with the dramatic increase in dia-
betes (DM) and accompanying vascular and neurological
complications [1,2]. Peripheral sensory neuropathy (PSN) is a
commonmicrovascular complication of both type 1 and type 2 DM,
and amajor cause of morbidity andmortality [3,4]. PSN plays amajor
contributing role in the initiation of foot ulceration and non-
traumatic lower-extremity amputation, resulting in severe disability,
reduced quality of life, and signiﬁcant economic burden to the health
care system [5]. From the theatre records at the Department of
Surgery, Korle-Bu Teaching Hospital, the main referral hospital in
Ghana, out of 518 non-traumatic limb amputations performedwithin
the period of January, 2014 through May, 2016, 467 (90.1%) were
DM-related cases, with 318 (68.1%) below the knee amputations per-
formed in DM patients.
Diagnosis of PSN is often made in clinical practice based on the
presence of signs and symptoms of peripheral nervous system after
other causes of neuropathy are excluded [3,6]. However, in up to
50% of DM patients, PSN may have no symptoms consistent with
neuropathy, and hence, further neurological examination may be
required for deﬁnite diagnosis [7,8]. Screening of PSN requires an
appropriate tool that can detect mild form of the disease in high
risk patients such as DM patients, and also, in low risk population
with high sensitivity. Hence, the Michigan neuropathy screening in-
strument (MNSI), which is widely used for the evaluation of PSN
in diabetes, was designed for such purpose [9]. Also, quantitative
vibration testing is recommended in the screening and diagnosis
of PSN [7]. However, this form of assessment is rarely performed
in studies reporting the burden of PSN in sub-Saharan Africa.
A recent review of literature on PSN concluded that there is
paucity of up-to-date epidemiological data on PSN worldwide [10],
with only one outdated study reported in African population [11].
Abbreviations: DM, diabetes mellitus; MNSI, Michigan neuropathy screening in-
strument; PSN, peripheral sensory neuropathy; VPT, vibration perception threshold.
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From our own literature search, we found a few current studies
that reported the burden of PSN in DM patients in African
population to be 27.3–48.2% [4,12,13]. In this study, we investi-
gated into the burden and determinants of PSN in DM patients and
non-DM participants using MNSI and vibration perception thresh-
old (VPT).
Methods
The study was case control design conducted at National Dia-
betes Management and Research Centre, Korle-Bu Teaching Hospital
in Accra, Ghana, from June 2009 to May 2010. The centre is Ghana’s
main referral clinic and operates ambulatory DM services and re-
search. DM patients were recruited by systematic sampling, as every
3rd consenting patient visiting the clinic. The controls were re-
cruited afterwards and matched with the DM patients by gender
and age-decade. The controls were non-DM with normal fasting
glucose (<6.9 mmol/l) and post-glucose load plasma glucose
(<7.2mmol/l), recruited randomly from the communities around the
hospitals. Out of 1000 volunteers (600 DM and 400 non-diabetes)
invited, 866 (516 DM and 350 non-diabetes) consented to partic-
ipate in the study. In the ﬁnal analysis, 31 diabetes (11 did not
complete the questionnaire and 20 had conﬂicting VPT results) and
20 non-diabetes participants (9 had impaired glucose metabolism
and 11 had conﬂicting VPT results) were excluded. Ethical approv-
al for this study was obtained from the University of Ghana Medical
School Ethical and Protocol Review Committee (Protocol ID number:
MS-Et/M.2 – P.4.10/2009–2010) and all participants gave written
informed consent after the procedures involved in the study were
thoroughly explained to them. A structured questionnaire was ad-
ministered to all the participants to collect information on age,
gender, education, employment status, duration of DM, DM med-
ication, pre-existing hypertension, smoking and alcohol status.
Second-hand smoking was assessed as living with a smoking rel-
ative or co-worker. Hypertension was deﬁned as subjects with
BP ≥140/90 mmHg and/or on antihypertensive medication.
Michigan neuropathy screening instrument
The MNSI questionnaire was administered to all participants by
a trained assistant. Responses were added to obtain a total score;
‘Yes’ responses to questions 1–3, 5–6, 8–9, 11–12, 14–15 were each
counted as one point and ‘No’ responses to questions 7 and 13 like-
wise counted as one point. Question 4 was considered to be a
measure of impaired circulation and question 10 a measure of
general asthenia and were excluded in the published scoring algo-
rithm [9]. A score of ≥7 was considered abnormal. In the MNSI
examination, a physician inspected each foot for deformities, dry
skin, calluses, infections and ﬁssures, and the presence of any ab-
normality was scored as 1. Also, ulceration on each foot was scored
as 1. The ankle reﬂexes were elicited and if absent, the patient was
asked to perform the Jendrassik manoeuvre. If the reﬂex was present
upon the Jendrassik, it was designated as present with reinforce-
ment and scored as 0.5. In the absence of reﬂex after the Jendrassik
manoeuvre, a score of 1 was assigned. Vibration sensation was then
tested on the great toe using a 128-Hz tuning fork. Generally, the
vibration is felt in the examiner’s hand for 5 seconds longer than
the a normal person can feel at the great toe. Vibration was scored
as present, if the examiner sensed the vibration on his or her hand
for not up to 10 s longer than the period the subject felt that vi-
bration on the great toe (scored as null); as decreased if the vibration
is sensed for ≥10 s (scored as 0.5); or absent (scored as 1) if no vi-
bration was felt at all. The total possible score is 8 points and, in
the published scoring algorithm, a score of ≥2.5 is considered ab-
normal [6].
Neurothesiometry
Neurothesiometry was performed using hand-held neuro-
thesiometer (Horwell Neurothesiometer, Scientiﬁc Laboratory Sup-
plies Ltd, Nottingham, UK) to read vibration perception threshold
(VPT) from the apex of the big toe of both legs, with subject in a
supine position, feet elevated with pillow support and eyes closed.
The neurothesiometer is a validated battery-operated diagnostic in-
strument that assesses sensitivity thresholds at various sites on the
body surface. On the basis of the method of limits, participants were
asked to indicate when they ﬁrst perceived vibration sensation after
stimulus was applied to the distal pulp of the toe. The intensity of
the stimulus was gradually increased at a rate of 0.5 V/s from null
to a voltage at which vibration was ﬁrst detected. VPT was per-
formed on each participant about 3–5 times and, at least, three VPTs
the differed ≤5 V were averaged and used for analysis. A null stim-
ulus test was added randomly to ensure participant adherence and
understanding of the test requirements. Participants who failed to
provide 3 consistent values of VPT within 5 V after several mea-
surements were excluded from the analysis as having conﬂicting
VPTs.
Statistical analysis
The data was analysed using IBM SPSS Version 20. Differences
in mean values of continuous were assessed using student’s t-test,
and distribution of categorical variables with χ2 test. Binary logis-
tic regression model was used to determine independent clinical
factors associated with PSN. p < 0.05 was considered statistically
signiﬁcant.
Results
DM patients were older, with higher proportion of hyperten-
sion, alcohol intake, and fewer current smokers than non-DM
controls. Also, DM patients had higher means of BMI, heart rate, sys-
tolic, diastolic, mean and pulse blood pressures, as well as higher
level of unemployment. Majority of the DM patients were on oral
hypoglycaemic medication. Compared to non-DM controls, preva-
lence of PSN screened by MNSI symptom score, examination scores
and VPT was higher in DM patients (Table 1). Among DM and non-
DM participants with PSN screened by the MNSI examination score,
majority were with the age range of 40–69 years, and predomi-
nantly females (Fig. 1a,b). However, when PSNwas screened by VPT,
the proportion of females with neuropathy was higher in DM pa-
tients, and the proportion of males was higher in non-DM
participant; majority of PSN patients were likewise within the age
range of 40–69 years (Fig. 2a,b).
Multivariable backward conditional logistic regression models
were constructed with PSN screened by MNSI symptoms, MNSI ex-
amination and VPT as dependent variables. In all participants, DM
status, age, heart rate, second-hand smoking and body height in-
creased the odds of abnormal VPT after multiple adjustments of risk
factors. In DM patients, age, duration of DM, heart rate and body
height increased the risk of prevalence of abnormal VPT; and in non-
DM controls, heart rate, body height increased the odds, whereas
being fully employed decreased the odds of abnormal VPT. With
respect to PSN screened byMNSI examination, DM status, age, female
gender, cigarette smoking andworking part-time increased the odds,
whereas working full-time decreased the odds of PSN in all par-
ticipants. In DM patients, age and female gender increased the odds
of PSN, whereas diastolic pressure decreased the odds of PSN. In
non-DM controls, alcohol use, cigarette smoking and working part-
time increased the odds of PSN, whereas working full-time decreased
the odds of PSN (Table 2).
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Table 1
General characteristics of study participants
All participants (n = 821) Diabetes patients (n = 491) Non-diabetes controls (n = 330) p
Age, yrs 52.6 ± 10.5 54.4 ± 10.4 51.9 ± 10.2 0.101
Gender (male), n (%) 368 (45.1) 212 (26) 156 (19.1) 0.79
Duration of diabetes, yrs 7.1 ± 6.2
Hypertension, n (%) 399 (48.7) 324 (39.6) 75 (9.1) <0.001
BMI, kg/m2 27.9 ± 7.8 29 ± 8.7 26.3 ± 5.8 <0.001
Height, cm 163 ± 11 162 ± 13 164 ± 8 0.038
Waist girth, cm 94 ± 24 95 ± 12 93 ± 34 0.442
Waist–hip ratio 0.93 ± 0.21 0.94 ± 0.07 0.91 ± 0.31 0.061
Systolic BP, mmHg 135 ± 26 144 ± 24 121 ± 22 <0.001
Diastolic BP, mmHg 80 ± 13 84 ± 13 74 ± 10 <0.001
Pulse BP, mmHg 55 ± 19 60 ± 18 48 ± 18 <0.001
Mean BP, mmHg 98 ± 15 104 ± 15 90 ± 11 <0.001
Heart rate, bpm 80 ± 13 82 ± 13 76 ± 12 <0.001
Smoking, n (%) 0.034
Current 36 (4.4) 10 (1.2) 26 (3.2)
Former 140 (17.1) 102 (12.4) 38 (4.7)
Never 635 (77.3) 367 (44.7) 268 (32.6)
Second-hand smoking 121 (14.7) 73 (8.9) 48 (5.8) 0.078
Alcohol, n (%) 225 (27.4) 115 (14) 110 (13.4) 0.002
Educational level 0.344
Up to elementary school 496 (60.5) 302 (36.9) 194 (23.6)
Higher than elementary 322 (39.5) 185 (22.7) 137 (16.8)
Employment 0.043
Unemployed 322 (39.2) 208 (25.3) 114 (13.9)
Part-time employment 49 (6) 27 (3.3) 22 (2.7)
Full-time employment 450 (54.8) 257 (31.3) 193 (23.5)
Diabetes medication, n (%) 0.012
Oral hypoglycaemics 318 (38.7)
Insulin 68 (8.3)
Insulin and oral hypoglycaemics 103 (12.5)
MNSI symptom score 2.5 ± 2.1 2.9 ± 1.8 2 ± 1.5 <0.001
MNSI examination score 2.2 ± 1.9 2.7 ± 2 1.5 ± 1.5 <0.001
Leg-speciﬁc VPT
Left great toe 16.1 ± 8.9 18.2 ± 9.1 13 ± 7.5 <0.001
Right great toe 15.3 ± 8.6 17.5 ± 9.2 12.2 ± 6.3 <0.001
Neuropathy, n (%)
VPT ≥25 V 163 (18.6) 125 (15.2) 28 (3.4) <0.001
MNSI symptom score ≥7 40 (5.3) 35 (4.7) 5 (0.6) <0.001
MNSI examination score ≥2.5 334 (40.7) 253 (30.8) 81 (9.9) <0.001
Table 2
Determinants of peripheral sensory neuropathy from multivariable logistic regression model
All participants Diabetes patients Non-diabetes
OR (95% CI) p OR (95% CI) p OR (95% CI) p
Abnormal VPT (≥25 V)
Diabetes 3.66 (2.26–5.95) <0.001
Age 1.04 (1.02–1.06) <0.001 1.05 (1.03–1.07) 0.001
Duration of diabetes 1.19 (1.03–2.140 0.021
Heart rate 1.02 (1.01–1.03) 0.047 1.03 (1.01–1.05) 0.019 3.17 (1.15–8.7) 0.025
SHS 1.78 (1.08–2.92) 0.023 – –
Height 3.28 (1.65–8.42) 0.015 2.33 (1.47–5.69) 0.01 2.01 (1.24–6.1) 0.006
Employed (reference: unemployed)
Part-time 2.84 (0.97–10.1) 0.067
Full-time 0.37 (0.14–0.95) 0.043
Abnormal MNSI examination score (≥2.5)
Diabetes 4.31 (2.94–6.31) <0.001
Age 1.03 (1.01–1.05) <0.001 1.03 (1.01–1.06) 0.002
Female 1.33 (0.96–1.83) 0.085 1.48 (1.01–2.18) 0.046
Insulin use 1.59 (0.92–2.77) 0.1 1.68 (0.96–2.92) 0.068
Alcohol 1.44 (1–2.08) 0.051 2.21 (1.15–4.25) 0.017
Systolic BP 1.01 (1–1.02) 0.077
Diastolic BP 0.98 (0.95–0.99) 0.018
Smoking (reference: non-smoking)
Previous 4.55 (2.11–9.82) <0.001 4.81 (1.98–11.66) 0.001
Current 8.16 (3.77–17.68) <0.001 9.53 (4.1–22.15) <0.001
Employment status (reference: unemployed)
Part-time 2.46 (1.23–4.92) 0.011 3.45 (1.29–9.21) 0.014
Full-time 0.77 (0.54–1.11) 0.155 0.48 (0.25–0.94) 0.032
Variables in the model included DM status, hypertension status, insulin therapy, age, body height, BMI, employment status, education, duration of DM (DM patient group),
alcohol intake, smoking status, second-hand smoking, systolic, diastolic, mean and pulse BPs. Backward conditional logistic regression model was applied.
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Discussion
PSN is a frequent complication of DM which has been diag-
nosed, historically, using symptoms, signs, quantitative sensory
testing and electrophysiological studies [8]. In Africa, few studies
that reported the burden of PSN in DM patients used question-
naire instrument or semi-quantitative methods [4]. These studies
are normally cross-sectional survey without appropriate non-DM
controls for comparison. In our study, we used case-control design
for comparison of PSN burden in DM patients and non-DM con-
trols. Also, PSNwas simultaneously diagnosed using symptom score,
physical examination and quantitative sensory test. The ﬁndings of
this study shows that the prevalence of PSN screened by MNSI
symptom score, MNSI examination score and VPT was 7.1%, 51.5%
and 24.5% in DM patients and 1.5%, 24.5% and 8.5% in non-DM par-
ticipants respectively. The major determinants of PSN by MNSI
examination score were diabetes status, age, female gender, insulin
therapy, alcohol use and employment status. Also, signiﬁcant de-
terminants of PSN by abnormal VPT were diabetes status, age, heart
rate, second-hand smoking and body height in all the participants.
The prevalence of PSN in Africa varies widely partly due to design
of the study, sample selection, and different diagnostic criteria em-
ployed (pin-prick perception, clinical signs and symptoms or semi-
quantitative sensory tests). Similar to the ﬁndings of our study, the
prevalence of PSN in diabetes patients was reported to be 48.2% and
47.1% in Ethiopia [12] and Libya [13], respectively, when screened
with questionnaire instrument. However, in Cameroon, the prev-
alence of PSN was reported to be 28% using symptom score from
clinical examination [14] and 27.3% using vibration perception from
a tuning fork [15]. From our literature search, we found no study
reporting the burden of PSN in non-DM sub-Saharan African pop-
ulation using quantitative sensory test like the VPT. Our ﬁndings
indicate that, compared to DM patients, the prevalence of PSN in
non-DM population is low, but gender and age-decade distribu-
tion of PSN in non-DM participants were similar to DM patients.
The ﬁndings of this study also show that PSN patients are prone
to work part-time, giving an indication that PSN may be associ-
ated with less productivity and economic cost [16].
The objective methods of assessing PSN are nerve conduction
studies and skin biopsies [3]. However, these methods are robust
requiring specially trained and experienced personnel, and may be
invasive as well, precluding their utility in resource-deprived sub-
Saharan African setting. Therefore, simple non-invasive clinical test,
like theMNSI, that assesses symptoms and signs of PSN can be easily
be applied in sub-Saharan African setting [17]. Since its introduc-
tion, the MNSI [9] has been widely used to assess PSN in clinical
practice and in large clinical trials, including the DCCT/EDIC [18],
ACCORD studies [19] and BARI 2D [20]. The MNSI has been vali-
dated to be accurate, reproducible, and well correlated with
neurologist conﬁrmed PSN [21]. Since the questionnaire items in
MNSI depend on the ability of the patient to understand and recall
appropriately the symptoms being described, patient-recall bias may
affect the performance of MNSI in screening for PSN.
VPT is the recommendedmethod of assessing PSN in populations-
based studies. VPT may provide important, clinically meaningful



























Figure 1. a). Gender distribution of peripheral sensory neuropathy by MNSQ ex-
amination score (≥2.5). b). Distribution of peripheral sensory neuropathy by MNSQ
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Figure 2. a). Gender distribution of peripheral sensory neuropathy by VPT (≥25V).
b). Distribution of peripheral sensory neuropathy by VPT (≥25V) across age decades.
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neurological symptoms associated with large ﬁbre neuropathy may
account for about 80% of the morbidity associated with PSN in DM
patients [3,8]. Abnormal VPT values had been shown to predict the
long-term complications of ulceration and amputation [6,22]. Some
critics of VPT testing suggest that it is not a suﬃcient measure of
peripheral nerve dysfunction and the results may be device-
biased [23], patient-dependent, affected by level of the patient’s
attentiveness, motivation, and fatigue [24]. In our study, to ensure
full patient’s cooperation, we thoroughly explained the procedure
of neurothesiometry to the participants, the nature of vibration ex-
pected was demonstrated on the arm before the test began, and
those with conﬂicting VPTs were excluded from analysis. VPT testing
was simple, quick to perform, painless, and generally well toler-
ated by our study participants.
The results of this study indicate that in both diabetes and non-
diabetes participants, MNSI examination score captured the highest
number of participants with PSN, followed by VPT, with MNSI
symptom score capturing the lowest number of PSN. As a ques-
tionnaire tool, MNSI symptom score may be limited by the patient’s
understanding and ability to appropriately recall the symptoms in-
volved. MNSI symptom score assesses general symptoms like
numbness, burning pain sensation, hypersensitivity and thermal sen-
sitivity, generally associated with small ﬁbre nerve damage [25].
Indeed, MNSI symptom score is reported to reﬂect loss of long nerve
ﬁbre bundle in the cornea and reduced corneal sensitivity [26],
markers of damage of small unmyelinated ﬁbres. In prediabetes pa-
tients, damage to small nerve ﬁbres is more common, but in diabetes
patients, large nerve ﬁbre damage predominates sensory neuropa-
thies [27]. Both MNSI examination and VPT involve assessment of
large nerve functions, which are most vulnerable to infarction in
diabetes patients. In MNSI examination, a physician specialist care-
fully examines foot symptoms, and also utilises standardised
techniques to screen for nerve damage assessment. However, the
outcomes of these screenings are binary (present or absent) and
hence, cannot measure the degree of nerve damage. The VPT can
independently assess the degree of large nerve damage andwas pre-
viously used as the gold method for neuropathy assessment [8].
The limitations of this study include cross-sectional data col-
lection, so we cannot infer causality or assess predictive utility of
the methods used to screen for PSN. Also, diabetes patients in the
study were recruited from a tertiary referral hospital and hence, the
ﬁndings of this study cannot be generalised to the entire diabetes
patients in Ghana. In addition, no plasma markers were measured
to evaluate the pathophysiological mechanisms underlying PSN in
sub-Saharan African population. The major strength of our study
is large sample size, with DM patients systematically selected, and
comparable age and gender of non-DM controls.
Conclusion
In summary, there is high burden of PSN in diabetes patients in
our study sample, using simple, non-invasive screening tools, yet
accurate tools such as MNSI and neurothesiometer. Future studies
may investigate the utility of these assessment tools and the patho-
physiological mechanisms underlying PSN in Ghanaian population.
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